Jove
Visualize
お問い合わせ
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 腫瘍学とがん発生
  5. 予測・予測マーカー
  6. Brca変異の状態は卵巣がんの発症タイミングと患者の治療結果に影響しますか?
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 腫瘍学とがん発生
  5. 予測・予測マーカー
  6. Brca変異の状態は卵巣がんの発症タイミングと患者の治療結果に影響しますか?

関連する実験動画

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
13:04

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

13.3K

BRCA変異の状態は卵巣がんの発症タイミングと患者の治療結果に影響しますか?

Kaja Michalczyk1, Agata Mokrzycka1, Marianna Rudzińska1

  • 1Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Powstancow Wielkopolskich 72, 70-111 Szczecin, Poland.

Genes
|August 28, 2025

PubMed で要約を見る

まとめ
この要約は機械生成です。

BRCA変異は卵巣がんの早期発症と関連しています. BRCA1変異は,高度の血清性卵巣がん患者の全生存率を改善し,明確な予後効果を示唆しています.

科学分野:

  • 腫瘍学
  • 遺伝学
  • 婦人科腫瘍学

背景:

  • BRCA1およびBRCA2遺伝子の変異は,卵巣がんのリスク要因として確立されています.
  • BRCA変異が卵巣がんに与える予後的な影響は完全に理解されていません.
  • 最も一般的なサブタイプは,高度の血清性卵巣がん (HGSOC) です.

研究 の 目的:

  • 卵巣がんの発症年齢に対する BRCA 変異状態の影響を調査する.
  • HGSOC患者における治療結果に対するBRCA変異状態の影響を評価する.
  • BRCA1とBRCA2のキャリアの予測の違いを分析する.

主な方法:

  • 新たに診断された25人のFIGOステージIII/ IV HGSOC患者の遡及分析.
  • 収集されたデータには,年齢,腫瘍組織学,CA125,BRCA変異の状態,および治療の詳細が含まれています.
  • 生存分析はカプラン・マイヤー法とログランクテストを用いた.

主要な成果:

  • BRCA変異のキャリアは,非キャリア (66. 81歳) と比較して,平均年齢が低い年齢で診断されました.
  • BRCA1キャリアは,診断時に最も若い年齢 (46. 52歳) でした.
キーワード:
BRCA1 についてBRCA2 についてHGSOC について卵巣がん

さらに関連する動画

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

14.8K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.3K

関連する実験動画

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
13:04

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

13.3K
Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

14.8K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.3K

関連する概念動画

Cancer Survival Analysis01:21

Cancer Survival Analysis

448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448
Tumor Progression02:07

Tumor Progression

6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

9.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
Oogenesis02:07

Oogenesis

64.3K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
64.3K
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー
  • 病変無生存期 (PFS) の有意な差は認められなかった. BRCA1変異のキャリアは全生存率 (OS) を改善したが,BRCA2のキャリアはそうではなかった.
  • 結論:

    • BRCA変異,特にBRCA1は卵巣がんの早期発症と関連しています.
    • BRCA1変異の状態は,HGSOCにおける全生存率の好ましい予後要因である.
    • この発見は,特定のBRCA変異の臨床的影響を強調し,さらなる研究が必要である.